ESMO Congress 2019
‘Living’ anticancer medicines: has a new era started?
The benefits of adoptive T-cell therapy—where T-cells are given to induce a specific immune response—are moving closer to reality for patients with solid tumours
Two CDK 4/6 inhibitors prolong survival in HR+/HER2- breast cancer in pre- and post-menopausal women
Results from the MONARCH 2 and MONALEESA-3 trials
Immunotherapy fails to improve PFS and OS in relapsed mesothelioma
Results from the PROMISE-meso trial presented
PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Towards diagnosis of minimal residual disease
Liquid biopsies are fast making their mark as a diagnostic test for minimal residual disease (MRD), providing guidance on how to tailor treatment for early-stage cancers